

Somatic Genetic Events Linked to the *Apc* Locus in Intestinal Adenomas of the Min Mouse

Cindy Luongo and William F. Dove

McArdle Laboratory for Cancer Research and Laboratory of Genetics, University of Wisconsin Medical School, Madison, Wisconsin

We have found previously that all spontaneous intestinal adenomas from *Apc*⁺/*Apc*^{Min} mice lose the wild type *Apc* marker on two genetic backgrounds. On the (AKR × B6)F₁ background, this event involves loss of the entire homolog of mouse chromosome 18 carrying *Apc*⁺. This chromosome carries both the *Mcc* and *Dcc* genes, which are homologs of genes that have been implicated in human colorectal cancer. To determine whether the loss of alleles of *Mcc* and/or *Dcc* is necessary for the formation of intestinal adenomas, subchromosomal somatic events were induced by γ -irradiation. The observed spectrum of intrachromosomal somatic genetic losses rules out a requirement for loss of heterozygosity at either locus during adenoma formation. Subchromosomal allelic losses linked to *Apc*⁺ occur spontaneously on other genetic backgrounds. In the majority of these events, the *Apc*⁺ allele itself was somatically lost, as judged by the wild type marker at the *Min* site. However, on the [*M. musculus castaneus* (CAST) × B6-Min]F₁ and (129/Sv × B6-Min)F₁ backgrounds, spontaneous adenomas were observed in which the wild type marker at the *Min* site was retained. Further analysis will be required to determine whether these exceptions involve intra-*Apc* mutations. If not, then these events would illustrate routes to intestinal neoplasia that do not require complete inactivation of wild type *Apc* function. *Genes Chromosom Cancer* 17:194-198 (1996).

Familial adenomatous polyposis (FAP) is one of the familial colon cancer syndromes of the human in which the genetic etiology is becoming understood. Germline mutations in the adenomatous polyposis coli (*APC*) gene are carried in heterozygous form in affected individuals of FAP families. The *APC* gene has been mapped to chromosomal region 5q21-22 of the human genome (Bodmer et al., 1987; Groden et al., 1991, 1995; Joslyn et al., 1991; Kinzler et al., 1991a; Nishisho et al., 1991). At the adenomatous polyp stage of intestinal neoplasia in FAP individuals and in sporadic cases, somatic genetic events are found to affect the wild type *APC* allele, often resulting in a truncated *APC* product (Solomon et al., 1987; Ashton-Rickardt et al., 1989, 1991; Miyaki et al., 1990; Miyoshi et al., 1992a,b; Powell et al., 1992; Nagase and Nakamura, 1993). To date, no case has been reported in which the entire homolog of human chromosome 5 carrying the normal *APC* allele is lost in intestinal polyps or tumors.

A mouse strain, *Min* (multiple intestinal neoplasia), has been produced by chemical mutagenesis of the mouse germline (Moser et al., 1990). This strain carries a nonsense mutation of *Apc*, the mouse homolog of *APC* (Su et al., 1992). The *Min* mouse matches human FAP families in the primary genetic lesion and in the predisposition to intestinal tumors and certain extracolonic manifestations (for review, see Dove et al., 1994, 1995); however, the *Min* mouse is not a perfect match to the corresponding human condition. Our goal in the work

reported here was to study the patterns of somatic genetic events linked to *Apc*⁺ in the adenomas that form in *Min* mice both spontaneously and after γ -irradiation.

To determine whether it is necessary to lose the wild type *Apc*⁺ allele in the adenomas of *Min* mice, we previously analyzed intestinal adenomas from *Apc*⁺/*Apc*^{Min} mice on two genetic backgrounds, C57BL/6/J (B6) and (AKR × B6-Min)F₁. We performed these analyses by determining the ratio of wild type (*Min*⁺) to mutant (*Min*) DNA fragments in polymerase chain reaction (PCR) products templated by DNA collected from sectioned tumor samples. The *Min*⁺/*Min* ratio was reduced greatly in all tumor samples (Luongo et al., 1994). The loss of *Apc*⁺ in (AKR × B6-Min)F₁ mice was accompanied by allelic losses at loci along the entire chromosome 18 homolog carrying *Apc*⁺. Loss of an entire chromosome is the most common mechanism of allelic loss in mouse tumors (Hegi et al., 1993; Dietrich et al., 1994; Luongo et al., 1994; Wiseman et al., 1994). This pattern of somatic events differs from that observed in human colorectal adenomas. One possible biological ex-

Received September 18, 1995; accepted July 16, 1996.

Cindy Luongo is currently at Bock Laboratories, University of Wisconsin, 1525 Linden Drive, Madison, WI 53706, U.S.A.

Address correspondence to William F. Dove, McArdle Laboratory, University of Wisconsin, 1400 University Avenue, Madison, WI 53706, U.S.A.

planation for this difference is that adenoma formation in the mouse requires loss of function at more than the *Apc* locus. For example, *Mcc* and *Dcc*, the mouse homologs of two genes implicated in human colorectal cancer (Fearon et al., 1991; Kinzler et al., 1991b), also map to mouse chromosome 18 (Justice et al., 1992; Luongo et al., 1993). One or both of these loci may also need to lose function when tumors form in *Min* mice. In the human genome, by contrast, *DCC* is not syntenic with *APC* and *MCC*.

To determine what region of chromosome 18 must undergo somatic loss, we induced intestinal adenomas by exposing neonatal *Min* mice to a single dose of γ -rays. Double-strand breaks in DNA caused by γ -rays can lead to interstitial deletions and chromosomal rearrangements (for review, see Breimer, 1988). Mice were irradiated sublethally with a single dose of 0.80 Gy at 9–12 days of age. This age span was chosen because carcinogenic treatment of mice prior to weaning has been shown to result in a higher rate of survival and intestinal adenoma induction compared with treatment at older ages (Abrams, 1951; Shoemaker et al., 1995).

The irradiated group consisted of 25 (AKR \times B6-*Min*)F₁ mice (10 *Apc*⁺/*Apc*^{Min} and 15 *Apc*⁺/*Apc*⁺). For controls, 15 nonirradiated (AKR \times B6-*Min*)F₁ mice were analyzed in parallel (nine *Apc*⁺/*Apc*^{Min} and six *Apc*⁺/*Apc*⁺). At 150 days of age, the mice were killed by CO₂ asphyxiation, and the intestinal tract from the duodenum to the colon was excised and processed as described in detail previously (Luongo et al., 1994). First, tumors from the entire intestinal tract were counted under a dissecting microscope at $\times 5$ magnification; then, individual tumor samples were collected. The average tumor multiplicity of the irradiated *Apc*⁺/*Apc*^{Min} mice was 28, whereas that of the untreated *Apc*⁺/*Apc*^{Min} mice was 8 (Fig. 1a). This increase in intestinal adenoma multiplicity is significant ($P = 0.002$; Wilcoxon rank sum test). Because no tumors were observed in irradiated or untreated (AKR \times B6)F₁ *Apc*⁺/*Apc*⁺ mice, the majority, if not all, of the adenomas in the irradiated mice depend on the germline *Min* mutation.

To determine whether these tumors remain heterozygous for loci on chromosome 18, we analyzed 55 intestinal adenomas and 23 normal intestinal tissue samples from nine irradiated mice by quantitative PCR, as described previously (Luongo et al., 1994). DNA was isolated from each tissue sample and analyzed for the ratio of wild type to mutant PCR product at the *Min* site and for the ratio of AKR to B6 product at three polymorphic loci on




Figure 1. Distribution of tumor number in γ -irradiated and untreated *Apc*⁺/*Apc*^{Min} mice. Tumor multiplicity is depicted by a scatter plot with each point representing the number of intestinal adenomas from a single animal. a: Distribution for (AKR \times B6-*Min*)F₁ *Apc*⁺/*Apc*^{Min} mice. Tumor numbers ranged from 4 to 11 (untreated) and from 3 to 54 (0.80 Gy). The mean tumor numbers, which are indicated by horizontal lines (\pm standard deviation), were 8 ± 3 (untreated) and 28 ± 16 (0.80 Gy). b: Distribution for B6-*Apc*⁺/*Apc*^{Min} mice. Tumor numbers ranged from 11 to 49 (untreated) and from 26 to 93 (0.55 Gy). The mean tumor numbers were 26 ± 9 (untreated) and 60 ± 17 (0.55 Gy). *Apc*, adenomatous polyposis coli; *Min*, multiple intestinal neoplasia.

chromosome 18: *D18Mit19*, *D18Mit14*, and *D18Mit33* (Fig. 2). The AKR alleles at these loci lie *cis* to the *Apc*⁺ allele in the F₁ animal. The unlinked marker *D7Mit38* was included in the *D18Mit33* PCRs as an internal control for the allelic loss analysis.

The predominant mechanism for *Apc*⁺ loss in intestinal adenomas after neonatal γ -irradiation of (AKR \times B6-*Min*)F₁ *Apc*⁺/*Apc*^{Min} mice remains homolog loss (Fig. 2). For 9 of the 55 adenomas, however, interstitial loss of chromosome 18 AKR alleles surrounding *Apc*⁺ was observed. Most, if




Figure 2. Allelic loss in γ -ray-induced intestinal adenomas from (AKR \times B6-Min) F_1 mice. Allelic loss was considered to have occurred in a sample if the adenoma/control value of Apc^+/Apc^{Min} was ≤ 0.5 (AKR allele loss) or ≥ 2.0 (B6 loss; see Luongo et al., 1994). Open squares indicate loss, and solid squares indicate retention of the AKR allele. No B6 allele loss was detected in any adenoma. Loci are shown in map order with distances in cM (Luongo et al., 1993, 1994; C. Luongo, unpublished results). These loci span 42.3 cM of the 60 cM length of mouse chromosome 18 (Johnson and Davison, 1994). Candidate suppressor genes *Mcc* and *Dcc* are indicated in boldface. ND, not done.

not all, of these nine cases of interstitial loss were caused by the neonatal γ -irradiation. Because γ -irradiation increased the intestinal adenoma multiplicity approximately 3.5-fold, 39 [95% confidence interval (CI), 31–47] of the 55 adenomas resulted from γ -irradiation.

Two specific loci on mouse chromosome 18, *Mcc* and *Dcc*, are candidates for controlling the progression of intestinal neoplasia. However, the marker *D18Mit33*, which lies between *Apc* and *Dcc*, remained heterozygous in 7 of the 51 adenomas in which the *Min*⁺ marker was lost (of 55 total adenomas; Fig. 2). In the remaining four adenomas, the *Min*⁺ marker was retained, and chromosome 18 remained heterozygous; these exceptions will be discussed below. Similarly, the marker *D18Mit14*, which lies between *Apc* and *Mcc*, remained heterozygous in three adenomas that had lost the *Min*⁺ marker (Fig. 2). Thus, allelic loss of neither *Mcc* nor *Dcc* is required for *Min*-induced adenoma formation. Loss of *Mcc* or *Dcc* was never observed without *Apc*⁺ loss. The *DCC* gene seems to be altered late in human colon cancer (see Fearon et al., 1991). Therefore, one may not expect *Dcc* to be involved in adenomagenesis in the Min mouse. To be completely certain that no somatic lesion has been incurred at the *Mcc* and *Dcc* loci in these cases of interstitial *Apc*⁺ loss, sequencing will be necessary.

Can neonatal γ -irradiation generate adenomas by a route that retains the wild type *Apc*⁺ function? Irradiated *Apc*^{+/Apc}⁺ wild type controls did not develop intestinal adenomas. Strikingly, 4 of the 55 adenomas analyzed from irradiated (AKR \times B6-Min) F_1 *Apc*^{+/Apc}^{Min} heterozygotes retained the

wild type *Apc* marker at the *Min* site (Fig. 2). It is possible that γ -irradiation can generate adenomas by a route that retains one wild type copy of *Apc*. For example, it may produce a lesion in a separate locus that interacts with the heterozygous *Min*^{+/+} state of the *Apc* locus. Alternatively, γ -irradiation may cause intragenic lesions that inactivate the wild type allele but that were not detected in our assay, which examined only the region of *Apc* surrounding the *Min* site.

To determine whether neonatal γ -irradiation of B6-*Apc*^{+/Apc}^{Min} mice also can generate tumors retaining the *Min*⁺ marker, we exposed 12 B6-*Apc*^{+/Apc}^{Min} and 14 *Apc*^{+/Apc}⁺ mice at 10 days of age to a single dose of 0.55 Gy. The irradiated mice and their untreated litter mates (47 *Apc*^{+/Apc}^{Min} and 61 *Apc*^{+/Apc}⁺) were scored for intestinal adenomas at 90 days of age. Treatment with γ -rays caused a 2.3-fold increase in intestinal adenoma multiplicity in *Apc*^{+/Apc}^{Min} mice (Fig. 1b; $P = 3.4 \times 10^{-6}$; Wilcoxon rank sum test). One of the irradiated *Apc*^{+/Apc}⁺ mice developed a single colonic adenoma, whereas none of the untreated *Apc*^{+/Apc}⁺ mice developed tumors.

Twenty-one colonic adenomas and three control tissue samples from three of the irradiated B6-*Apc*^{+/Apc}^{Min} mice were analyzed for the presence of the *Min*⁺ marker by quantitative PCR (Luongo et al., 1994). Of these 21 adenomas, 9 were radiation induced (95% CI, 3–15). The ratio of *Min*⁺ to *Min* markers was calculated for each DNA sample. The individual *Min*^{+/Min} ratios did not exceed 0.33 for the adenomas (average, 0.15 ± 0.08), whereas the ratios for the normal tissue controls were 0.51 or greater (average, 0.70 ± 0.26). This difference is highly significant ($P = 9.68 \times 10^{-4}$; Wilcoxon rank sum test), indicating that all of the adenomas showed extensive loss of the *Min*⁺ marker. Thus, in this limited set of tumors on the B6 genetic background, no instance of *Min*-induced adenomagenesis has yet been found involving an intragenic lesion in the *Apc*⁺ gene or mutation of another locus that interacts with the *Apc*^{+/Apc}^{Min} state.

On the (AKR \times B6-Min) F_1 genetic background, spontaneous adenomas lost the alleles of all scored loci on chromosome 18 linked to *Apc*⁺ in each of 50 tumors (Luongo et al., 1994). To determine whether certain heterozygous genetic backgrounds would show a different pattern of spontaneous somatic genetic events, we surveyed F_1 hybrids in which the AKR parent was replaced either by DBA/2 (DBA), 129/Sv (129), or *M. musculus castaneus* (CAST). Spontaneous intestinal adenomas




Figure 3. Allelic loss in spontaneous intestinal adenomas from F_1 Apc^+/Apc^{Min} mice. The genetic backgrounds are (DBA \times B6-Min; a), (129 \times B6-Min; b), and [*M. musculus castaneus* (CAST) \times B6-Min; c]. Open squares indicate loss of the non-B6 allele (adenoma/control value of $Apc^+/Apc^{Min} \leq 0.5$). Solid squares indicate retention of the non-B6 allele. No B6 allele loss was seen in any adenoma (adenoma/control value of $Apc^+/Apc^{Min} \geq 2$). The chromosome 18 loci are shown in map order. ND, not done.

were analyzed for allelic loss of the markers *D18Mit19*, Min^+ , *D18Mit33*, and *D7Mit38* (as a control). Allelic loss of the control marker *D7Mit38* occurred in 3.5% (3/86, including those studied by Luongo et al., 1994) of all adenomas analyzed, independent of genetic background. This loss frequency is within the range (0–4%) seen for non-chromosome 18 markers (Luongo et al., 1994). The results of these studies are summarized in Figure 3.

Among the small set of five spontaneous adenomas analyzed on the (DBA \times B6) F_1 background, one instance of subchromosomal allelic loss was found that can be explained either by mitotic recombination between the *D18Mit19* and *Apc* loci or by terminal deletion (Fig. 3a). Among 25 adenomas analyzed on the (129 \times B6) F_1 background, we found nine cases of subchromosomal allelic loss (Fig. 3b). These data differ very significantly from those observed on the (AKR \times B6-Min) F_1 background ($P = 4 \times 10^{-6}$; Fisher's exact test). One case of retention of the Min^+ marker was noted on this F_1 hybrid background; such a situation has also been observed by Laird and his colleagues (1995).

On the (CAST \times B6) F_1 genetic background, one of nine spontaneous adenomas showed subchromosomal losses of markers linked to Apc^+ . Strikingly, in three other cases, the wild type fragment at the *Min* site was retained (Fig. 3c). This pattern of retention of at least the Min^+ fragment of *Apc* in the (CAST \times B6-Min) F_1 hybrid differs significantly from the spontaneous loss of the entire Apc^+ chromosome observed in (AKR \times B6-Min) F_1 tumors ($P = 0.003$; Fisher's exact test). We do not know the genetic basis for the difference between F_1 hybrids involving AKR and those involving CAST in the pattern of somatic events leading to *Min*-induced adenomas. The *Mom1* locus that affects the multiplicity of adenomas in *Min* mice carries a resistance allele in both AKR and CAST (Dietrich et al., 1993). Thus, this locus cannot provide a simple explanation for this difference.

All of the intestinal tumors analyzed were classified histologically as adenomas. No correlation was detected between subchromosomal allelic loss and adenoma histology or size (data not shown). Thus, there is no evidence that loss of alleles at loci on chromosome 18 other than *Apc* affects intestinal tumorigenesis.

In summary, we have found conditions of γ -irradiation and of genetic background in which somatic allelic losses linked to the *Apc* locus in the intestinal adenomas of *Min* mice are subchromosomal. The *Mcc* and *Dcc* loci can each remain heterozygous in these tumors. In a few cases, even the site of the *Min* mutation in *Apc* remains heterozygous. In these few cases, clearly, it is important to determine now whether mutations have arisen within the Apc^+ allele, inactivating its function while retaining the Min^+ marker.

The *Min* mouse strain is being developed as a model of human FAP colon cancer families and, by inference, sporadic colon cancer in humans. To this end, the observations reported here indicate that it may be possible to place the Apc^{Min} mutation on a genetic background on which the major somatic pathways for loss of the wild type Apc^+ allele would include intragenic mutation, interstitial deletion, or mitotic recombination in addition to loss of the wild type chromosome. Such a second-generation *Min* strain would represent a model that would share more fully both the germline and somatic genetic features of FAP in the human.

We have demonstrated that the somatic genetic events linked to *Apc* do not need to include losses of either *Mcc* or *Dcc*. Further studies can now address whether, under any circumstances, adenomas can form in Apc^+/Apc^{Min} heterozygotes by a path-

way that retains one functional wild type *Apc* allele (see Solomon et al., 1987; D'Abaco et al., 1996).

ACKNOWLEDGMENTS

We thank M.K. McNeley for the intestinal adenomas from (DBA \times B6-Min) F_1 mice, A.R. Moser for helpful critique and the communication of unpublished results, K.A. Gould and A.R. Shoemaker for continuing discussions, and L. Clipson and I. Riegel for detailed assistance with the article. This is publication number 3468 from the Laboratory of Genetics. This work was supported by grant CA63677, training grant CA09135, and core grant CA07075 from the National Cancer Institute.

REFERENCES

- Abrams HL (1951) Influence of age, body weight, and sex on susceptibility of mice to the lethal effects of x-radiation. *Proc Soc Exp Biol Med* 76:729-732.
- Ashton-Rickardt PG, Dunlop MG, Nakamura Y, Morris RG, Purdie CA, Steel CM, Evans HJ, Bird CC, Wylie AH (1989) High frequency of *APC* loss in sporadic colorectal carcinomas due to breaks clustered in 5q21-22. *Oncogene* 4:1169-1174.
- Ashton-Rickardt PG, Wylie AH, Bird CC, Dunlop MG, Steel CM, Morris RG, Piris J, Romanowski P, Wood R, White R, Nakamura Y (1991) *MCC*, a candidate familial polyposis gene in 5q21, shows frequent allele loss in colorectal and lung cancer. *Oncogene* 6:1881-1887.
- Bodmer WF, Bailey CJ, Bodmer J, et al. (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. *Nature* 328:614-616.
- Breimer LH (1988) Ionizing radiation-induced mutagenesis. *Br J Cancer* 57:6-18.
- D'Abaco GM, Whitehead RH, Burgess AW (1996) Synergy between *Apc^{min}* and an activated *ras* mutation is sufficient to induce colon carcinomas. *Mol Cell Biol* 16:884-891.
- Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W (1993) Genetic identification of *Mom-1*, a major modifier locus affecting *Min*-induced intestinal neoplasia in the mouse. *Cell* 75:631-639.
- Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES (1994) Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. *Proc Natl Acad Sci USA* 91:9451-9455.
- Dove WF, Luongo C, Connelly CS, Gould KA, Shoemaker AR, Moser AR, Gardner RL (1994) The adenomatous polyposis coli gene of the mouse in development and neoplasia. *Cold Spring Harbor Symp Quant Biol* 59:501-508.
- Dove WF, Gould KA, Luongo C, Moser AR, Shoemaker AR (1995) Emergent issues in the genetics of intestinal neoplasia. *Cancer Surveys* 25:335-355.
- Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas R, Kinzler KW, Vogelstein B (1991) Identification of a chromosome 18q gene that is altered in colorectal cancers. *Science* 247:49-56.
- Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albersen H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, LePasler D, Abderrahim H, Cohen D, Leppert M, White R (1991) Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 66:589-600.
- Groden J, Joslyn G, Samowitz W, Jones D, Bhattacharyya N, Spirio K, Thliveris A, Robertson M, Egan S, Meuth M, White R (1995) Response of colon cancer cell lines to the introduction of *APC*, a colon-specific tumor suppressor gene. *Cancer Res* 55:1531-1539.
- Hegi ME, Soderkvist P, Foley JF, Schoonhoven R, Swenberg JA, Kari R, Maronpot R, Anderson MW, Wiseman RW (1993) Characterization of *p53* mutations in methylene chloride-induced lung tumors from B6C3 F_1 mice. *Carcinogenesis* 14:803-810.
- Johnson KR, Davison MT (1994) Mouse chromosome 18. *Mamm Genome* 5(Suppl):S259-S265.
- Joslyn G, Carlson M, Thliveris A, Albersen H, Gelbert L, Samowitz W, Groden J, Stevens J, Spirio L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, LePasler D, Abderrahim H, Cohen D, Leppert M, White R (1991) Identification of deletion mutations and three new genes at the familial polyposis locus. *Cell* 66:601-613.
- Justice MJ, Gilbert DJ, Kinzler KW, Vogelstein B, Buchberg AM, Ceci JD, Matsuda Y, Chapman VM, Patriotic C, Makris A, Tschilis PN, Jenkins NA, Copeland NG (1992) A molecular genetic linkage map of mouse chromosome 18 reveals extensive linkage conservation with human chromosomes 5 and 18. *Genomics* 13:1281-1288.
- Kinzler KW, Nilbert MC, Su L-K, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, Finnear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I, Nakamura Y (1991a) Identification of FAP locus genes from chromosome 5q21. *Science* 253:661-665.
- Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, Carlson M, Joslyn G, Groden J, White R, Miki Y, Miyoshi Y, Nishisho I, Nakamura Y (1991b) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. *Science* 251:1366-1370.
- Laird PW, Jackson-Grusby L, Fazeli A, Dickinson S, Jung WE, Li E, Weinberg RA, Jaenisch R (1995) Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 81:197-205.
- Luongo C, Gould KA, Su L-K, Kinzler KW, Vogelstein B, Dietrich W, Lander ES, Moser AR (1993) Mapping of multiple intestinal neoplasia (*Min*) to proximal chromosome 18 of the mouse. *Genomics* 15:3-8.
- Luongo C, Moser AR, Gledhill S, Dove WF (1994) Loss of *Apc⁺* in intestinal adenomas from Min mice. *Cancer Res* 54:5947-5952.
- Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K, Kikuchi R, Iwama T, Ikeuchi T, Tomonura A, Nakamura Y, White R, Miki Y, Utsunomiya J, Koike M (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. *Cancer Res* 50:7166-7173.
- Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler KW, Vogelstein B, Nakamura Y (1992a) Germ-line mutations of the *APC* gene in 53 familial adenomatous polyposis patients. *Proc Natl Acad Sci USA* 89:4452-4456.
- Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y (1992b) Somatic mutations of the *APC* gene in colorectal tumors: mutation cluster region in the *APC* gene. *Hum Mol Genet* 1:229-233.
- Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science* 247:322-324.
- Nagase H, Nakamura Y (1993) Mutations of the *APC* (adenomatous polyposis coli) Genet Hum Mutat 2:425-434.
- Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P, Markham A, Krush AJ, Petersen G, Hamilton SR, Nilbert MC, Levy DB, Bryan TM, Preisinger AC, Smith KJ, Su L-K, Kinzler KW, Vogelstein B (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 253:665-669.
- Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW (1992) *APC* mutations occur early during colorectal tumorigenesis. *Nature* 359:235-237.
- Shoemaker AR, Moser AR, Dove WF (1995) ENU treatment of Min mice: Age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts. *Cancer Res* 55:4479-4485.
- Solomon E, Voss R, Hall V, Bodmer WF, Jass JR, Jeffreys AJ, Lucibello FC, Patel I, Rider SH (1987) Chromosome 5 allele loss in human colorectal carcinomas. *Nature* 328:616-619.
- Su L-K, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the *APC* gene. *Science* 256:668-670.
- Wiseman RW, Cochran C, Dietrich W, Lander ES, Soderkvist P (1994) Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3 F_1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. *Proc Natl Acad Sci USA* 91:3759-3763.